Aptamer Group plc, a developer of next-generation synthetic binders for the life sciences industry, has signed a significant development contract with a top 3 global pharmaceutical company to engineer Optimer binders as targeted radiopharmaceuticals for potential therapeutic applications.
Dr Arron Tolley, CEO of Aptamer Group, said: “This significant contract win with a top 3 global pharmaceutical company marks a key expansion of our platform into targeted radiopharmaceuticals and potential therapeutics.”
The new £360,000 ($483,000) fee-for-service development contract is to develop Optimer binders as targeted radiopharmaceuticals with potential applications in therapeutics. Aptamer retains rights for future licensing revenues upon commercialization, positioning the Company for future downstream licensing and/or royalty revenue streams.
This program will engineer Optimers targeting an undisclosed cancer target. Preliminary work will develop tools for Positron Emission Tomography (PET) imaging with a view to translating to therapeutic applications. The Optimer platform offers advantages for this application area, including enhanced tumor penetration, reduced immunogenicity, and ease of chemical optimization.
The contract expands the application of the Company’s Optimer technology into the growing targeted radiopharmaceuticals market, valued at $7.5 billion in 2025, and represents the second therapeutic modality under development by Aptamer alongside targeted gene therapy.
Read More
Aptamer entered two other development contracts for its Optimer binders earlier this year.